ABSTRACT
Given the expansion of genetics in medicine, there is a growing need to develop approaches to engage patients in understanding how genetics affects their health. Various qualitative methods have been applied to gain a deeper understanding of patient perspectives in topics related to genetics. Community dialogues (CD) are a bi-directional research method that invites community members to discuss a pertinent, challenging topic over the course of a multi-week period and the community members openly discuss their positions on the topic. Authors discuss the first application of the CD method to the topic of pharmacogenetics testing. Additional CD are needed to engage diverse participant populations on this topic to improve genetics literacy, enhance physician engagement and drive policy change.
Subject(s)
Health Literacy/ethics , Pharmacogenetics/ethics , Pharmacogenomic Testing/ethics , Precision Medicine/ethics , Bioethical Issues/standards , Focus Groups/standards , Health Literacy/standards , Humans , Pharmacogenetics/standards , Pharmacogenomic Testing/standards , Precision Medicine/standardsABSTRACT
PURPOSE: Preemptive pharmacogenetic testing aims to optimize medication use by having genetic information at the point of prescribing. Payers' decisions influence implementation of this technology. We investigated US payers' knowledge, awareness, and perspectives on preemptive pharmacogenetic testing. METHODS: A qualitative study was conducted using semistructured interviews. Participants were screened for eligibility through an online survey. A blended inductive and deductive approach was used to analyze the transcripts. Two authors conducted an iterative reading process to code and categorize the data. RESULTS: Medical or pharmacy directors from 14 payer organizations covering 122 million US lives were interviewed. Three concept domains and ten dimensions were developed. Key findings include clinical utility concerns and limited exposure to preemptive germ-line testing, continued preference for outcomes from randomized controlled trials, interest in guideline development, importance of demonstrating an impact on clinical decision making, concerns of downstream costs and benefit predictability, and the impact of public stakeholders such as the Food and Drug Administration and Centers for Medicare and Medicaid Services. CONCLUSION: Both barriers and potential facilitators exist to developing cohesive reimbursement policy for pharmacogenetics, and there are unique challenges for the preemptive testing model. Prospective outcome studies, more precisely defining target populations, and predictive economic models are important considerations for future research.
Subject(s)
Pharmacogenomic Testing/economics , Pharmacogenomic Testing/ethics , Pharmacogenomic Testing/trends , Adult , Decision Making , Delivery of Health Care , Female , Health Personnel , Humans , Male , Middle Aged , Pharmacists , Pharmacogenetics/methods , Qualitative Research , Stakeholder Participation , Surveys and Questionnaires , United StatesABSTRACT
No disponible
